Terms: = Lung cancer AND EXT1, ttv, 2131, ENSG00000182197, EXT, Q16394
51 results:
1. Evaluation of a New Method for CyberKnife Treatment for Central lung and Mediastinal Tumors by Tracheobronchial Tracking.
Suzuki T; Saito M; Takahashi H; Suzuki H; Makino K; Ueda K; Mochizuki K; Mochizuki Z; Nemoto H; Sano N; Onishi H
Technol Cancer Res Treat; 2024; 23():15330338241232557. PubMed ID: 38378006
[TBL] [Abstract] [Full Text] [Related]
2. Identification of LGR4 as a prognostic biomarker in KRAS-mutant lung adenocarcinoma: Evidence from integrated bioinformatics analysis.
Dodin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36084. PubMed ID: 37986325
[TBL] [Abstract] [Full Text] [Related]
3. Comparison and Validation of Rapid Molecular Testing Methods for Theranostic Epidermal Growth Factor Receptor Alterations in lung cancer: Idylla versus Digital Droplet PCR.
Léonce C; Guerriau C; Chalabreysse L; Duruisseaux M; Couraud S; Brevet M; Bringuier PP; Poncet DA
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958668
[TBL] [Abstract] [Full Text] [Related]
4. Finding a Novel Chalcone-Cinnamic Acid Chimeric Compound with Antiproliferative Activity against MCF-7 Cell Line Using a Free-Wilson Type Approach.
Ventura-Salazar IAY; Palacios-Can FJ; González-Maya L; Sánchez-Carranza JN; Antunez-Mojica M; Razo-Hernández RS; Alvarez L
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513358
[TBL] [Abstract] [Full Text] [Related]
5. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
[TBL] [Abstract] [Full Text] [Related]
6. Prediction of KRAS
Srisongkram T; Khamtang P; Weerapreeyakul N
J Mol Graph Model; 2023 Jul; 122():108466. PubMed ID: 37058997
[TBL] [Abstract] [Full Text] [Related]
7. Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessment.
Wang C; Zhu H; Huang H; Sun Z; Teng Y; Li Y
Future Oncol; 2023 Jan; 19(3):259-270. PubMed ID: 36891950
[TBL] [Abstract] [Full Text] [Related]
8. Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts.
Grahovac M; Spielvogel CP; Krajnc D; Ecsedi B; Traub-Weidinger T; Rasul S; Kluge K; Zhao M; Li X; Hacker M; Haug A; Papp L
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1607-1620. PubMed ID: 36738311
[TBL] [Abstract] [Full Text] [Related]
9. Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India.
Kulshrestha R; Saxena H; Kumar R; Spalgais S; Mrigpuri P; Goel N; Menon B; Rani M; Mahor P; Bhutani I
Monaldi Arch Chest Dis; 2023 Feb; 93(4):. PubMed ID: 36723380
[TBL] [Abstract] [Full Text] [Related]
10. Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study.
Srisongkram T; Weerapreeyakul N
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614109
[TBL] [Abstract] [Full Text] [Related]
11. Surgical resection versus radiotherapy for clinical stage IA lung cancer ≤1 cm in size: A population-based study.
Huang W; Deng HY; Wu XN; Xu K; Li P; Lin MY; Yuan C; Zhou Q
Asian J Surg; 2023 Jan; 46(1):385-393. PubMed ID: 35525696
[TBL] [Abstract] [Full Text] [Related]
12. Prevalence and severity of symptoms and signs in patients with advanced cancer in the last days of life: the East Asian collaborative cross-cultural study to elucidate the dying process (EASED).
Hiratsuka Y; Suh SY; Won SH; Kim SH; Yoon SJ; Koh SJ; Kwon JH; Park J; Ahn HY; Cheng SY; Chen PJ; Yamaguchi T; Morita T; Tsuneto S; Mori M; Inoue A
Support Care Cancer; 2022 Jun; 30(6):5499-5508. PubMed ID: 35304634
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic impact of count of extratumoral lymphatic permeation in lung adenocarcinoma and its relation to the immune microenvironment.
Niimi T; Nakai T; Aokage K; Tane K; Miyoshi T; Samejima J; Miyazaki S; Taki T; Sakamoto N; Sakashita S; Watanabe R; Kojima M; Suzuki K; Tsuboi M; Ishii G
Cancer Sci; 2022 Apr; 113(4):1497-1506. PubMed ID: 35181964
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab.
Eude F; Guisier F; Salaün M; Thiberville L; Pressat-Laffouilhere T; Vera P; Decazes P
Ann Nucl Med; 2022 Mar; 36(3):224-234. PubMed ID: 35060071
[TBL] [Abstract] [Full Text] [Related]
15. Risk factors for in-hospital mortality in patients with advanced lung cancer with interstitial pneumonia undergoing systemic chemotherapy: A retrospective and observational study using a nationwide administrative database in Japan.
Shiraishi T; Oda K; Yamasaki K; Kido T; Sennari K; Mukae H; Ohtani M; Fujino Y; Matsuda S; Fushimi K; Yatera K
Thorac Cancer; 2022 Jan; 13(2):236-246. PubMed ID: 34865321
[TBL] [Abstract] [Full Text] [Related]
16. Neutrophils correlate with hypoxia microenvironment and promote progression of non-small-cell lung cancer.
Zhang C; Tang B; Hu J; Fang X; Bian H; Han J; Hou C; Sun F
Bioengineered; 2021 Dec; 12(1):8872-8884. PubMed ID: 34637697
[TBL] [Abstract] [Full Text] [Related]
17. Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell lung cancer (SCLC) in China.
Gong J; Wan Q; Shang J; Qian X; Su D; Sun Z; Liu G
Adv Ther; 2021 Oct; 38(10):5116-5126. PubMed ID: 34417989
[TBL] [Abstract] [Full Text] [Related]
18. Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease.
Otani T; Yamaguchi K; Nakao S; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Cancer Chemother Pharmacol; 2021 Nov; 88(5):857-865. PubMed ID: 34350479
[TBL] [Abstract] [Full Text] [Related]
19. Torque Teno Virus load in lung cancer patients correlates with age but not with tumor stage.
Stefani D; Hegedues B; Collaud S; Zaatar M; Ploenes T; Valdivia D; Elsner C; Bleekmann B; Widera M; Dittmer U; Aigner C
PLoS One; 2021; 16(6):e0252304. PubMed ID: 34077485
[TBL] [Abstract] [Full Text] [Related]
20. Volatile constituents and in vitro activity of Syzygium aromaticum flower buds (clove) against human cancer cell lines.
Sara -; Begum S; Ali SN; Farooq AD; Siddiqui F; Siddiqui BS; Ayub A; Fatima M
Pak J Pharm Sci; 2020 Nov; 33(6):2659-2665. PubMed ID: 33867344
[TBL] [Abstract] [Full Text] [Related]
[Next]
